Nastech Pharmaceutical Company Inc.

Nastech Pharmaceutical Company Inc. announced the initiation of a Phase 2 clinical trial to evaluate the company’s short-acting insulin nasal spray in 20 patients with type 2 diabetes. The study is a randomized, crossover study to evaluate insulin nasal spray formulations to Novolog insulin aspart , a licensed, fast-acting injectable insulin, compared to post – meal glucose control.

Nastech and our collaboration partners are developing products for multiple therapeutic areas including osteoporosis, obesity, diabetes, autism, respiratory and inflammatory diseases. Among the factors that distinguish which could cause actual results to differ materially differ differ in forward-looking statements include, but are not limited to: the ability of Nastech to obtain additional financing, the ability of Nastech to attract and / or maintain production research, development and commercialization partners, Nastech and / or a partner’s ability to successfully complete product research and development, including preclinical and clinical studies and commercialization; Nastech and / or a partner required the ability to ,ls, and Nastech and / or a partner’s ability to develop and commercialize products of competitors favorably with those of competitors.Health care department the District of Columbia and NYC also told common influenza activity, the Center for Disease Prevention and Control. The agency said, flu-like illness overall rise, but in some areas., Including Texas and Colorado, two countries that been particularly hard hit by the flu early in decline the season.

The Center for Disease Control and Prevention, the grippe said distributed status achieved – to the CDC the highest breakout levels – in 10 countries and since last week: Alabama, Maryland, Michigan, Minnesota, New Jersey, South Dakota and Wisconsin.

Random entries

Other entries from category "clinical":